logo
Share SHARE
FONT-SIZE Plus   Neg

Baxter: FDA Approves Rixubis For Routine Prophylactic Treatment In Hemophilia B

Baxter International Inc. (BAX) said the United States Food and Drug Administration has approved Rixubis for routine prophylactic treatment, control of bleeding episodes, and perioperative management in adults with hemophilia B.

Rixubis is the first new recombinant factor IX or rFIX approved for hemophilia B in more than 15 years. It is the only rFIX indicated for both routine prophylaxis and control of bleeding episodes in the U.S. for adult patients living with this chronic condition.

Hemophilia B is the second most common type of hemophilia. It is the result of insufficient amounts of clotting factor IX, a naturally occurring protein in blood that controls bleeding.

The approval is based on a Phase I/III study demonstrating that twice-weekly prophylactic treatment with Rixubis for six months achieved a median annualized bleed rate or ABR of 2.0 with 43 percent of patients experiencing no bleeds.

In this study, no patients developed an inhibitory antibody to FIX and no cases of anaphylaxis were reported. One patient developed a transient antibody to furin.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
HP launched a new slim Chromebook 11 G5 with a touchscreen. It will hit the market in October. Dow Chemical Co. announced a series of actions to achieve synergy capture from the restructuring of its ownership of the Dow Corning Corporation. The collective actions will result in a reduction of approximately 2,500 positions globally, or approximately four percent of Dow's workforce. South Korea's Fair Trade Commission or FTC is investigating Apple over some matters related to the tech giant in that country, Reuters reported, citing the head of the anti-competition body. FTC Chairman Jeong Jae-chan talked about the investigation during a parliamentary hearing on Tuesday, but has not disclosed further details.
comments powered by Disqus
Follow RTT